Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: Curtis Frazier who wrote (317)	5/12/1998 5:11:00 PM
From: Doug Meetmer	Read Replies (2) \| Respond to of 717

What are you talking about? ENMD rose so precipitously because people perceived the company to have discovered the "cure" for cancer. In addition, Thomas Watson said that he thought the disoverer would win the Nobel prize for this!! In additon, the director of (? NCI vs. NIH) said that they would give priority to studies with the two antiangiogenesis drugs. In additon, there was an article in the NYT outlining how great the effects in Mice were. Pharmacyclics on the other hand is not perceived to have discovered the cure for cancer. They will report data about a radiation sensitizer. The stock deserves to be up because there really isnt a good radiation sensitizer out there now, AND with continued good clinical data the company is growing that much closer to FDA approval for their radiation sensitizer. In addition, there are numerous other studies underway for their radiation sensitizer in many cancers. Also, I want to point out that if Lu-Tex turns out to work for peripheral vascular disease, this stock will be a five bagger overnight. As far as I know, they haven't yet started trials for this indication, however. I feel very confident that PCYC will be trading above $35 and possibly above $38 when the data is announced next week. Today's pullback was healthy profit taking for a stock that had been on a tear lately.